Acifran

CAS No. 72420-38-3

Acifran( —— )

Catalog No. M33827 CAS No. 72420-38-3

Acifran (AY 25712) is an HM74A/GPR109A and GPR109B agonist and displays antihyperlipidemic activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 61 Get Quote
5MG 73 Get Quote
10MG 123 Get Quote
25MG 242 Get Quote
50MG 394 Get Quote
100MG 561 Get Quote
500MG 1152 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Acifran
  • Note
    Research use only, not for human use.
  • Brief Description
    Acifran (AY 25712) is an HM74A/GPR109A and GPR109B agonist and displays antihyperlipidemic activity.
  • Description
    Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    GPR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    72420-38-3
  • Formula Weight
    218.21
  • Molecular Formula
    C12H10O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (572.84 mM; Ultrasonic )
  • SMILES
    CC1(OC(=CC1=O)C(O)=O)c1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. M N Cayen, et al. The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs. Xenobiotica. 1986 Mar;16(3):251-63. ?
molnova catalog
related products
  • DJ-V159

    DJ-V159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A).

  • NIBR189

    NIBR189 is a potent and selective antagonist of EBI2 (GPR183) receptor ?(IC50 of 11 and 15 nM for human and mouse EBI2 receptors respectively).

  • Myristyl nicotinate

    Myristyl nicotinate is an ester prodrug being developed for delivery of nicotinic acid (NIC) into the skin for prevention of actinic keratosis and its progression to skin cancer.